A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Status:
Completed
Trial end date:
2011-04-21
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the efficacy and safety of intermittent oral Xeloda plus
Eloxatin (oxaliplatin) with that of fluorouracil/leucovorin in patients who have had surgery
for colon cancer and no previous chemotherapy. Patients will be randomized to receive either
1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or
2)5-fluorouracil + leucovorin in 4 or 8 week cycles. The anticipated time on study treatment
is until disease progression and the target sample size is 500+ individuals.